基质金属蛋白酶与糖尿病性动脉粥样硬化

journal6 ›› 2006, Vol. 27 ›› Issue (5): 109-112.

基质金属蛋白酶与糖尿病性动脉粥样硬化

(1.吉首大学医学院,湖南吉首 416000；2.中南大学湘雅二医院内分泌科,湖南长沙 410011）

出版日期:2006-09-25 发布日期:2012-06-29
作者简介:沙永红（1969－），女，湖南省桃源县人，吉首大学医学院副教授，主要从事糖尿病研究.
基金资助:
湖南省教育厅科学研究项目（04C488）

Relationship Between Matrix Metalloproteinases and Atherosclerosis in Diabetics Mellitus

（1.College of Medicine,Jishou University,Jishou 416000,Hunan China;2.Institute of Metabolism and Endocrinology,the Second Xiangya Hospital,Central South University,Changsha 410011,China）

Online:2006-09-25 Published:2012-06-29

摘要/Abstract

摘要：糖尿病并动脉粥样硬化（As）是糖尿病（DM）常见的慢性大血管并发症，DM死亡率中动脉粥样硬化占80%.基质金属蛋白酶（MMPs）与DM合并As的关系密切，MMPs在细胞外基质（ECM）动态平衡、组织重塑、修复等病理生理过程中起重要作用.DM合并As患者循环MMPs水平升高，提示MMPs在DM血管病变的发生、发展中起重要作用.应用干预措施降低MMPs产物活性有助于阻抑DM血管病变的发生、发展.

关键词： 糖尿病, 动脉粥样硬化, 基质金属蛋白酶

Abstract: As a common chronic macrovalcular disease of diabetes mellitus (DM),Atherosclerosis (As) accounts for 80% mortality of DM.MMPs is knowed closely related to As in DM,and plays important roles in homeostasis of ECM,tissue remodelling and rehabilitating.High level of MMPs detected in diabetic patients with As suggests that MMPs may be important in the development and progressing of diabetic vascular disease.It would be helpful for preventing and restraining diabetic vascularopathy when targeting to decrease the level of MMPs.

Key words: diabetes mellitus, atherosclerosis, matrix metalloproteinases

沙永红, 唐炜立. 基质金属蛋白酶与糖尿病性动脉粥样硬化[J]. journal6, 2006, 27(5): 109-112.

SHA Yong-Hong, TANG Wei-Li. Relationship Between Matrix Metalloproteinases and Atherosclerosis in Diabetics Mellitus[J]. journal6, 2006, 27(5): 109-112.

参考文献

[1] SHAPITO S D.Matrix Metalloproteinase Degradation of Extracellular Matrix:Biological Consequences [J].Curr. Opin. Cell Biol.,1998,10:602-608.

[2] ALLAN J A,DOCHERTY A J,BARKER P J,et al.Binding of Gelatinases A and B to Type-I Collagen and Other Matrix Components [J].Biochem. J.,1995,309:299-306.

[3] KOLB C,MAUCH S,PETER H H,et al.The Matrix Metalloproteinase RASI-1 is Expressed in Synovial Blood Vessels of a Rheumatoid Arthritis Patient [J].Immunol. Lett.,1997,57:83-88.

[4] CELENTANO D C,FRISHMAN W H.Matrix Metalloproteinases and Coronary Artery Disease:A Novel Therapeutic Target [J].J. Clin. Pharmacol.,1997,37(11):991-1 000.

[5] YE S,WATTS G F,MANDALIA S,et al.Preliminary Report:Genetic Variation in the Human Stromelysin Promoter is Associated with Progression of Coronary Ather Osclerosis [J].Br. Heart J.，1995，73:209-215.

[6] MORGAN A R,ZHANG B,TAPPER W,et al.Haplotypic Analysis of the MMP-9 Gene in Coronary Artery Disease [J].J. Mol. Med.，2003，81(5):321-326.

[7] POLLANEN P J,KARHUNEN P J,MIKKELSSON J,et al.Coronary Artery Complicated Lesion Area is Related to Functional Polymorphism of Matrix Metalloproteinase 9 Gene:An Autopsy Study [J].Arterioscler. Thromb. Vasc. Biol.，2001，21(9):1 446-1450.

[8] WEI M,MITCHELL B D,HAFLNER S M,et al.Effect of Cigarette Smok8ing Diabetes,Nigh Cholesterol,and Hypertension on Aucause Mortality and Cardiovascular Disease Mortality in Mexican Americans：The San Antonio Heart Study [J].Am. J. Epidemiol.,1996,144：1 058-1 065.

[9] SKYLER J S,MARKS J B,SCHNEIDERMAN N.Hypertension in Patients with Diabetes [J].Am. J. Hypertens.,1995,8:100-105.

[10] ESPOSITO C,GERLACH H,BRETT J,et al.Endothelial Receptor-Mediated Binding of Glucose-Modified Albumin is Associated with Increased Monolayer Permeability and Modulation of Cell Surface Coagulant Properties [J].J. Exp. Med.,1989,170:1 387-1 407.

[11] LOPES-VIRELLA M F,VIRELLA G,ORCHARD T J,et al.Antibodies to Oxidized LDL and LDL-Containing Immune Complexes as Risk Factors for Coronary Artery Disease in Diabetes Mellitus [J].Clin. Immunol.,1999,90:165-172.

[12] SUZUKI D,MIYAZAKI M,JINDE K,et al.In Situ Hybridization Studies of Matrix Metalloproteinase-3,Tissue Inhibitor of Metalloproteinase-1 and IV Collagen in Diabetic Nephropathy [J].Kidney Int.,1997,52(1):111-119.

[13] DEATH A K,FISHER E J,MCGRATH K C,et al.High Glucose Alters Matrix Metalloproteinase Expression in Two Key Vascular Cells:Potential Impact on Atherosclerosis in Diabetes [J].Atherosclerosis,2003,168(2):263-269.

[14] MARX N,FROEHLICH J,SIAM L,et al.Antidiabetic PPAR Gamma-Activator Rosiglitazone Reduces MMP-9 Serurn Levels in Type 2 Diabetic Patients with Coronary Artery Disease [J].Arterioscler. Thromb. Vasc. Biol.,2003,23(2):283-288.

[15] LOBMANN R,AMBROSCH A,SCHULTZ G,et al.Expression of Matrix-Metalloproteinases and Their Inhibitors in the Wounds of Diabetic and Non-Diabetic Patients [J].Diabetologia,2002,45(8):1 011-1 016.

[16] 郭立新,汪恕萍,李萍,等.基质金属蛋白酶9与糖尿病大血管的关系 [J].中华内分泌代谢杂志,2002,12(6):471-472.